Recent Press Releases

Celltrion files for US FDA approval of Remsima

Celltrion files for US FDA approval of Remsima Remsima® is expected to be the first biosimilar monoclonal antibody to be filed through United States of America Food and Drug Administration's...

Verizon Helps Kids Be Kids at Diabetes Summer Camp

Company's Network and Technology Enable Trial of Artificial Pancreas in California

NEW YORK, Aug.

Access to Abbott's MitraClip® System Expands in the U.S. with Medicare National Coverage Determination

- Medicare will Provide National Coverage for People with Severe Degenerative Mitral Regurgitation Deemed Too Sick for Surgery

ABBOTT PARK, Ill.,

Sanofi Launches Authorized Generic Version of Eloxatin® (oxaliplatin injection)

BRIDGEWATER, N.J., Aug. 12, 2014 /PRNewswire/ -- Sanofi US announced today that it has launched an authorized generic version of Eloxatin® (oxaliplatin injection) through Winthrop US, the...

Synta Reports Second Quarter Financial Results and Provides Corporate Update

Synta Reports Second Quarter Financial Results and Provides Corporate Update Webcast and Conference Call Today, August 6, at 10:00 AM ET LEXINGTON, Mass.--(BUSINESS WIRE)--Aug. 6, 2014-- Synta...

Synta Names Anne Whitaker Chief Executive Officer

Synta Names Anne Whitaker Chief Executive Officer LEXINGTON, Mass.--(BUSINESS WIRE)--Aug. 6, 2014-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that Anne Whitaker will join the Company...

FDA Approves VELCADE® (bortezomib) Retreatment in Patients with Multiple Myeloma

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company with its parent company, Takeda Pharmaceutical Company Limited (TSE:4502), today announced that the U.S. Food and Drug...

First half year 2014: Boehringer Ingelheim meets challenges

Net sales of around €6.5 billion achieved in the first half year Preparations for additional product launches in full swing Initiative to improve cost structure launched Ingelheim,...

EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME)

EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME) TARRYTOWN, N.Y., Aug. 11, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN...

Novo Nordisk increased operating profit in local currencies by 12% in the first six months of 2014

Novo Nordisk increased operating profit in local currencies by 12% in the first six months of 2014 7% sales growth in local currencies driven by Levemir® and Victoza® Sales increased by 7% in...

Regeneron Reports Second Quarter 2014 Financial and Operating Results

- Second quarter 2014 EYLEA® (aflibercept) Injection global net sales increased 53% to $662 million (consisting of $415 million in the U.S. and $247 million in rest of world(1)) versus second...

GSK's COPD.com Relaunch Promotes Understanding and Dialogue about COPD

New site is filled with information, patient testimonials, easy-to-use tools and real-world tips for people affected by COPD

RESEARCH TRI

Screening and Drug Therapy Predicted to Make Hepatitis C a Rare Disease

Screening and Drug Therapy Predicted to Make Hepatitis C a Rare Disease Newly implemented screening guidelines and improved, highly effective drug therapies could make hepatitis C a rare disease in...

Merck Completes Tender Offer to Acquire Idenix

Merck Completes Tender Offer to Acquire Idenix WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced the successful completion of...

Actavis Net Revenue Increases 34% to $2.67 Billion in Second Quarter 2014; Non-GAAP EPS Increases 70% to $3.42

Actavis Net Revenue Increases 34% to $2.67 Billion in Second Quarter 2014; Non-GAAP EPS Increases 70% to $3.42 - Second Quarter 2014 GAAP Earnings Per Diluted Share of $0.28 - - 82% Increase in...

Type 2 diabetes: Jentadueto® (linagliptin and metformin hydrochloride) tablets label updated to include new data on blood glucose reductions in treatment-naive adults with high baseline A1C

- Combination of linagliptin and metformin significantly reduced blood glucose levels compared with linagliptin alone

RIDGEFIELD, Conn.

Amgen Announces Phase 3 ASPIRE Trial Of Kyprolis® In Patients With Relapsed Multiple Myeloma Met Primary Endpoint

Kyprolis Helped Patients Live 8.7 Months Longer Without Their Disease Worsening

THOUSAND OAKS, Calif. and

Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit

Desperate Allergan Attempt to Interfere with the Special Meeting LAVAL, Quebec and NEW YORK, Aug. 1, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) and Pershing...